Enhanced Oral Bioavailability of Etodolac by the Liquisolid Compact Technique: Optimisation, In-Vitro and In-Vivo Evaluation

Author(s): Bhumin K. Pathak, Meenakshi Raghav, Arti R. Thakkar, Bhavin A. Vyas, Pranav J. Shah*

Journal Name: Current Drug Delivery

Volume 18 , Issue 4 , 2021

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: Poor dissolution of Etodolac is one of the major challenges in achieving the desired therapeutic effect in oral therapy.

Objective: This study aimed to assess the potential of the liquisolid compact technique in increasing the rate of dissolution of Etodolac and thus its bioavailability.

Methods: Liquisolid compacts were prepared using PEG 400, Avicel PH-200 and Aerosil 200 as non-volatile liquid, carrier and coating material, respectively. The optimisation was carried out by applying a 32 full factorial design using Design expert software to examine the effects of independent variables (load factor and carrier: coating ratio) on dependent variables (angle of repose and % cumulative drug release at 30 min [Q 30 min]). Assessment of bioavailability was based on a pharmacokinetic study on rabbits and pharmacodynamics evaluation on rats, respectively.

Results: The formulation M3 was identified as the optimised formulation based on the better flow (lower angle of repose) and a higher rate of dissolution (Q 30 min >95%). The higher dissolution rate could be due to conversion of Etodolac into an amorphous molecularly dispersed state, availability of larger surface area, enhancement of aqueous solubility and enhanced wetting of drug particles. Studies with DSC, XRD, and SEM verified the transformation of Etodolac from crystalline to amorphous state, a key factor responsible for improving the dissolution rate. The pharmacokinetic profile of M3 was prominent, demonstrating higher absorption of Etodolac in comparison to oral suspension and immediate-release conventional tablets in rabbits. Liquisolid formulation exhibited a 27% increment in paw thickness as compared to 57% and 46% increments for oral suspension and immediate-release conventional tablets, respectively, after 7 hrs in the carrageenan-induced paw model in rats.

Conclusion: The results indicated the liquisolid compact technique to be a promising strategy to enhance the bioavailability of Etodolac.

Keywords: Immediate release tablet, liquisolid compact technique, dissolution profile, pharmacokinetics, carrageenan-induced paw oedema, capsules.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 27 May, 2021
Page: [471 - 486]
Pages: 16
DOI: 10.2174/1567201817666201026111559
Price: $65

Article Metrics

PDF: 68